These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25109873)

  • 1. Killing two birds with one stone: the potential role of aripiprazole for patients with comorbid major depressive disorder and nicotine dependence via altering brain activity in the anterior cingulate cortex.
    Chu CS; Tzeng NS; Chang HA; Chang CC; Chen TY
    Med Hypotheses; 2014 Sep; 83(3):407-9. PubMed ID: 25109873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bupropion. An antidepressant used to help smoking cessation].
    Taeron C
    Rev Infirm; 2002 May; (81):47-9. PubMed ID: 12078615
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjunctive aripiprazole for bupropion-resistant major depression.
    Sokolski KN
    Ann Pharmacother; 2008 Jul; 42(7):1124-9. PubMed ID: 18492784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of bupropion for smoking cessation.
    Richmond R; Zwar N
    Drug Alcohol Rev; 2003 Jun; 22(2):203-20. PubMed ID: 12850907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bupropion in the treatment of major depressive disorder in real-life practice.
    Sennfelt DA; Marques da Silva MA; Tavares AP
    Clin Drug Investig; 2011 Oct; 31 Suppl 1():19-24. PubMed ID: 22015859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain reward system activity in major depression and comorbid nicotine dependence.
    Cardenas L; Tremblay LK; Naranjo CA; Herrmann N; Zack M; Busto UE
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1265-71. PubMed ID: 12183688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychopharmacology of smoking cessation in patients with mental illness.
    Selby P
    J Psychiatry Neurosci; 2006 Sep; 31(5):360. PubMed ID: 16951737
    [No Abstract]   [Full Text] [Related]  

  • 8. The efficacy and tolerability of bupropion in the treatment of major depressive disorder.
    Moreira R
    Clin Drug Investig; 2011 Oct; 31 Suppl 1():5-17. PubMed ID: 22015858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacological treatments for nicotine dependence.
    George TP; O'Malley SS
    Trends Pharmacol Sci; 2004 Jan; 25(1):42-8. PubMed ID: 14723978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole: a dopamine modulator that mimics methylphenidate in producing faster antidepressant effects.
    Chen TY; Tzeng NS
    Med Hypotheses; 2013 Aug; 81(2):183-5. PubMed ID: 23751312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits.
    Hays JT; Ebbert JO
    CNS Drugs; 2003; 17(2):71-83. PubMed ID: 12521356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.
    Lerman C; Jepson C; Wileyto EP; Epstein LH; Rukstalis M; Patterson F; Kaufmann V; Restine S; Hawk L; Niaura R; Berrettini W
    Neuropsychopharmacology; 2006 Jan; 31(1):231-42. PubMed ID: 16123753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
    Han DH; Kim SM; Choi JE; Min KJ; Renshaw PF
    J Psychopharmacol; 2013 Mar; 27(3):282-91. PubMed ID: 23325372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
    Jefferson JW; Pradko JF; Muir KT
    Clin Ther; 2005 Nov; 27(11):1685-95. PubMed ID: 16368442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
    Pae CU; Lim HK; Han C; Patkar AA; Steffens DC; Masand PS; Lee C
    Expert Rev Neurother; 2007 Oct; 7(10):1251-63. PubMed ID: 17939764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of treating cathinone dependence and comorbid depression using bupropion.
    Lev-Ran S
    J Psychoactive Drugs; 2012; 44(5):434-6. PubMed ID: 23457895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    Dhir A; Kulkarni SK
    Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoking cessation.
    Frankenburg FR
    JAMA; 2005 Nov; 294(19):2434; author reply 2435. PubMed ID: 16287951
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of bupropion hydrochloride for smoking cessation therapy.
    Nichols MR
    Clin Excell Nurse Pract; 1999 Nov; 3(6):317-22. PubMed ID: 10865568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.